DRIVE Stack (PT-141 + MT-2)
Libido + tan combo.
- Sizes available
- —
- Lab certificate (COA)
- Arrives with shipment
· Research-grade only · Not for human consumption · 21+ ·
PT-141 + MT-2 libido + tan combo stack.
Mechanism · Two-compound melanocortin blend (MC4R + MC1R/MC4R).
Best for. Not for.
Best for
- Users pursuing a combined libido and tan effect (blend efficiency)
- Users with prior PT-141 and MT-2 monotherapy experience (ready for the blend stage)
Not for
- First-time PT-141 or MT-2 users; confirm monotherapy tolerance first
- Cardiovascular instability; both compounds affect blood pressure
- Mole / atypical nevus many people
- Pregnancy / planned pregnancy
Mechanism, dose, ramp, risk.
- Mechanism
- Two-compound blend.Source · PEPVERA editorial
- Target dose
- Per protocol.Source · PEPVERA editorial
- Ramp
- 8 weeks.Source · PEPVERA editorial
- Risks
- Per components.Source · PEPVERA editorial
Compared to its siblings.
DRIVE Stack (PT-141 + MT-2)
PT-141 + MT-2 libido + tan combo stack.
Pros
- · Combined libido and tan effect in one protocol, versus PT-141 libido-only.
- · Component-level options after monotherapy graduation.
Cons
- · No independent FDA approval; PT-141 has Vyleesi 2019 label.
- · Includes tan side effect, unlike PT-141.
- · Two-vial protocol versus MT-2 single-vial simplicity.
PT-141 (Bremelanotide)
Libido-only. FDA Vyleesi 2019 specifically label.
Pros
- · FDA approval
- · No tan side-effect
Cons
- · No tan effect.
See PT-141 (Bremelanotide) →
Melanotan 2
Tan and libido in a single-molecule option, simpler than a blend.
Pros
- · Single vial
Cons
- · No FDA approval
- · Mole discoloration stronger
See Melanotan 2 →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 0 suppliers
No verified suppliers yet for this compound.
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Week 1–2
Per protocol.
Initiation
Week 3–4
Per protocol.
Signal emerges
Week 5–8
Per protocol.
Hold
Week 9–12
Cycle review
Assess
Draw 20 units.
1 mg = 0.20 mL at 5.00 mg/mL. 10.0 doses per vial.
drive · VIII
DRIVE Stack (PT-141 + MT-2) · 10mg